As a progressive condition, diabetes presents an ongoing challenge for physicians to provide adequate control of patients’ disease, and new agents with novel mechanisms of action help reduce the burden in the management of diabetes.
As a progressive condition, diabetes presents an ongoing challenge for physicians to provide adequate control of patients’ disease, and new agents with novel mechanisms of action help reduce the burden in the management of diabetes.
In a recent Peer Exchange discussion, Peter Salgo, MD, of Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, led a discussion on novel agents and their role in treating patients with and without cardiovascular disease. On the panel was Om Ganda, MD, of Joslin Diabetes Center; Jim Kenney of JTKenney, a managed care consulting practice; and Helena Rodbard, MD, FACP, MACE, past president of the American College of Endocrinology and past president of the American Association of Clinical Endocrinologists.
Here, you can listen to part of the discussion.
Listen above or through one of these podcast services:
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Diabetes Risk Driven by Economic Disparity in Hispanic, Latino Communities
March 28th 2025Hispanic and Latino adults found that while preserving cultural identity may initially benefit health, socioeconomic factors like education level significantly impact diabetes and hypertension rates, highlighting the need for targeted health interventions across diverse subgroups.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More